In postmenopausal women with low to very
low bone mass, High-intensity exercise under supervision for 8
months do not cause fragility fractures and helps to improve thoracic kyphosis.
High-intensity resistance and
impact training (HiRIT) exercise for eight months improves thoracic kyphosis
and donot cause fragility fractures among postmenopausal females having low to
very low bone mass, evident from a randomized, controlled, single-blind, exercise
intervention LIFTMOR trial.
The LIFTMOR trial described a
novel, HiRIT program that enhanced bone mass among postmenopausal women with
osteoporosis and osteopenia but evaluation of the safety of HiRIT in the
osteoporosis demographic was unidentified. Thus, this analysis was conducted to
evaluate the risk of vertebral fracture during HiRIT among postmenopausal
females with low bone mass by assessing Cobb angle, vertebral body morphology,
and clinical measures of thoracic kyphosis.
Selected participants were
categorized to either low-intensity, unsupervised, home-based exercise (CON) or
eight months of 30-min, supervised, twice-weekly HiRIT. Lateral thoracolumbar
DXA scans were conducted at baseline and follow-up. Semiquantitative Genant
method was performed to identify the vertebral fracture. Clinical kyphosis
quantifications were done in standing tall and relaxed standing (neutral
posture) using a flexicurve and an inclinometer.
In comparison to CON, HiRIT
provided significant decline in inclinometer-determined standing tall thoracic
kyphosis. Both CON and HiRIT groups displayed within-group progress in kyphosis
in relaxed standing. HiRIT group showed no variations in vertebral fracture
classification. CON group exhibited a new, single and wedge deformation.
Participants treated with supervised HiRIT exhibited no increased risk of
vertebral fracture. All these findings support the HiRIT for postmenopausal
females with low to very low bone mass.
Osteoporos Int.
High-intensity exercise did not cause vertebral fractures and improves thoracic kyphosis in postmenopausal women with low to very low bone mass: the LIFTMOR trial.
S. L. Watson et al.
Comments (0)